Table 1B.
Baseline Characteristics of the Four Treatment Groups, As treated (N=22)
| Placebo | Paroxetine | Fluconazole | Paroxetine + Fluconazole | |
|---|---|---|---|---|
|
| ||||
| n=5 | n=8 | n=3 | n=6 | |
|
| ||||
| Age, years, median (IQR) | 49 (47, 61) | 51.5 (48.5, 54) | 56 (49, 57) | 50.5 (50, 53) |
|
| ||||
| Education, years, median (IQR) | 12 (12, 12) | 12 (12, 13) | 13 (12, 14) | 11.5 (10, 13.) |
|
| ||||
| Gender | ||||
| Male (%) | 3 (60) | 6 (75) | 3 (100) | 2 (33.3) |
| Female (%) | 1 (20) | 2 (25) | 0 | 3 (50) |
| Trans (%) | 1 (20) | 0 | 0 | 1 (16.7) |
|
| ||||
| Race, (% African-American) | 4 (80) | 5 (62.5) | 3 (100) | 5 (83.3) |
|
| ||||
| CD4 count, median (IQR) | 419 (359, 485) | 535.5 (413, 815.5) | 290 (269, 525) | 534.5 (389, 630) |
|
| ||||
| Plasma HIV RNA, copies/ml, median (IQR) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.64) |
|
| ||||
| Plasma HIV RNA, % <50 copies/ml | 4 (80) | 7 (87.5) | 3 (100) | 4 (66.7) |
|
| ||||
| Hepatitis C, serology % positive | 5 (100) | 1 (12.5) | 2 (66.7) | 2 (33.3) |
|
| ||||
| CES-D, median (IQR) | 13 (10.25) | 2.5 (0.5, 4.5) | 20 (18.27) | 9 (3.14) |
IQR, interquartile range (25th and 75th percentile)
CES-D Center for Epidemiological Studies-Depression scale